Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Poynard

Showing results (61-70 of 272) with videos related to

Pageof 28
Sort By:
Hepatology (Baltimore, Md.)|November 13, 2008
Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiencyPascal Lebray, Shaïda Varnous, Fréderic Charlotte, et al.
The American Journal of Gastroenterology|October 3, 2002
Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis CRobert P Myers, Vlad Ratziu, Françoise Imbert-Bismut, et al.
Antiviral Therapy|July 21, 2004
In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovirOlivier Lada, Yves Benhamou, Annie Cahour, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|November 26, 2009
Evaluation of FibroTest inter-laboratory variations requires standardization on analytical systems and should not be mixed with underpowered histological validationMona Munteanu, Françoise Imbert-Bismut, Chantal Housset, et al.
Expert Review of Molecular Diagnostics|September 26, 2007
FibroMAX: towards a new universal biomarker of liver disease?Rachel Morra, Mona Munteanu, Françoise Imbert-Bismut, et al.
European Journal of Internal Medicine|August 16, 2003
Sarcoidosis and interferon therapy: report of five cases and review of the literatureStéphanie Leclerc, Robert P. Myers, Joseph Moussalli, et al.
AIDS (London, England)|April 20, 2004
Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapyRobert P Myers, Yves Benhamou, Marie Bochet, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|June 24, 2008
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experienceMona Munteanu, Vlad Ratziu, Rachel Morra, et al.
Hepatology (Baltimore, Md.)|January 28, 2006
Diagnostic value of FibroTest with normal serum aminotransferasesThierry Poynard, Mona Munteanu, Yen Ngo, et al.
Journal of Hepatology|December 17, 2005
Natural history and predictors of disease severity in chronic hepatitis CJulien Massard, Vlad Ratziu, Dominique Thabut, et al.
Pageof 28

Showing results (61-70 of 272) with videos related to

Sort By:
Pageof 28
Hepatology (Baltimore, Md.)|November 13, 2008
Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiencyPascal Lebray, Shaïda Varnous, Fréderic Charlotte, et al.
The American Journal of Gastroenterology|October 3, 2002
Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis CRobert P Myers, Vlad Ratziu, Françoise Imbert-Bismut, et al.
Antiviral Therapy|July 21, 2004
In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovirOlivier Lada, Yves Benhamou, Annie Cahour, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|November 26, 2009
Evaluation of FibroTest inter-laboratory variations requires standardization on analytical systems and should not be mixed with underpowered histological validationMona Munteanu, Françoise Imbert-Bismut, Chantal Housset, et al.
Expert Review of Molecular Diagnostics|September 26, 2007
FibroMAX: towards a new universal biomarker of liver disease?Rachel Morra, Mona Munteanu, Françoise Imbert-Bismut, et al.
European Journal of Internal Medicine|August 16, 2003
Sarcoidosis and interferon therapy: report of five cases and review of the literatureStéphanie Leclerc, Robert P. Myers, Joseph Moussalli, et al.
AIDS (London, England)|April 20, 2004
Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapyRobert P Myers, Yves Benhamou, Marie Bochet, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|June 24, 2008
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experienceMona Munteanu, Vlad Ratziu, Rachel Morra, et al.
Hepatology (Baltimore, Md.)|January 28, 2006
Diagnostic value of FibroTest with normal serum aminotransferasesThierry Poynard, Mona Munteanu, Yen Ngo, et al.
Journal of Hepatology|December 17, 2005
Natural history and predictors of disease severity in chronic hepatitis CJulien Massard, Vlad Ratziu, Dominique Thabut, et al.
Pageof 28